Monday - April 14, 2025
ENGLEWOOD, Colo., Dec. 22, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been ranked 11th on Forbes list of America's Best Small Companies for 2023. The 2023 Forbes list of America's Best Small Companies can be found at www.forbes.com.
"We are incredibly honored to be recognized by Forbes for the third consecutive year. Our ranking of #11 this year is up from #57 on the 2022 list. These results are a true testament to the hard work and dedication of the Zynex team and serve as a reminder of the company's commitment to improving patients' lives," said Thomas Sandgaard, CEO and founder of Zynex Inc. "Additionally, we are thrilled to be listed as the #1 company in the Healthcare Equipment & Services industry and third in the overall healthcare sector. 2022 was a year of tremendous growth and success for Zynex, and we are proud of the impact we have made in the industry."
The data used to analyze the companies on the list was compiled from FactSet. Forbes screened over 1,000 small cap companies and narrowed the list down to 541 of which had positive sales growth over the past twelve months and a share price of at least $5. The rankings are based on a multitude of factors including earnings growth, sales growth, return on equity and total stock return for the trailing twelve months and over the last five years.
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
650 Fifth Ave., Suite 2720
New York, NY 10019
ir@zynex.com
Last Trade: | US$2.21 |
Daily Change: | 0.02 0.92 |
Daily Volume: | 194,334 |
Market Cap: | US$70.230M |
December 12, 2024 December 05, 2024 October 24, 2024 September 04, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load